GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active:	No
Cancer Type:	Cervical Cancer Lung Cancer	NCT ID:	NCT03917381
Trial Phases:	Phase I Phase II	Protocol IDs:	GCT1046-01 (primary) NCI-2020-03735
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genmab
NCI Full Details:	http://clinicaltrials.gov/show/NCT03917381

Summary

The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as
monotherapy and in combination therapies in patients with malignant solid tumors

Objectives

The trial is an open-label, multi-center safety trial of acasunlimab (GEN1046). The trial
consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion
part (phase 2a)). The expansion part of the trial will be initiated once the Recommended
Phase 2 Dose (RP2D) has been determined.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.